Butterfly Medical Ltd

Butterfly Medical Ltd is an innovative medical technology company that develops advanced implantable devices aimed at treating Benign Prostatic Hyperplasia (BPH), focusing on minimally invasive solutions for improved patient recovery. Founded in 2014, Butterfly Medical Ltd is headquartered in Yokneam Illit, Israel. The company specializes in developing an implantable device for the treatment of Benign Prostatic Hyperplasia (BPH). In its history, Butterfly Medical has undergone a strategic focus on creating less invasive solutions for patients.

The company was co-founded by Yehuda Bachar and is currently led by CEO Idan Geva. In May 2026, Butterfly Medical Ltd raised USD 21 million in series C funding from European Innovation Council, Junson Capital, MedVenture Partners, and New Rhein Healthcare Investors. Butterfly Medical specializes in the development of an innovative, implantable device designed to treat Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate affecting many men, particularly those over 60. This minimally invasive solution eliminates the need for cutting or tissue removal, which may improve patient recovery times and reduce complications tied to traditional surgical methods.

The device has received CE Mark approval for use in Europe and is positioned for investigational use in the United States. The company targets healthcare providers and urologists seeking effective treatment options for patients with BPH symptoms and is actively working in European markets while preparing for entry into the U. S. market.

Butterfly Medical's revenue model is based on direct sales of its implantable BPH treatment device to healthcare providers and urology centers. Transactions typically involve negotiations with hospitals and clinics, allowing for bulk purchase agreements to streamline procurement. The company may explore partnerships with larger medical device distributors to expand its market reach. While specific pricing plans are not disclosed, the revenue model incorporates one-time sales transactions and potential ongoing service agreements for product maintenance and support, fostering long-term relationships with healthcare providers.

The company plans to utilize the May 2026 funding to prepare for commercialization and further regulatory efforts for its non-surgical benign prostatic hyperplasia solution.